

# Contents

## 1. Introduction

|            |                              |    |
|------------|------------------------------|----|
| <b>1.1</b> | <b>Historical Highlights</b> | 21 |
| 1.1.1      | Bloodletting                 | 21 |
| 1.1.2      | Plasmapheresis               | 25 |
| <b>1.2</b> | <b>Definitions</b>           | 28 |

## 2. Methods

|            |                                                                                                     |    |
|------------|-----------------------------------------------------------------------------------------------------|----|
| <b>2.1</b> | <b>Membrane Plasmapheresis</b>                                                                      | 35 |
| 2.1.1      | Single-Needle Plasmapheresis (SN-TPE)                                                               | 35 |
| 2.1.2      | Other Devices for Plasmapheresis                                                                    | 40 |
| 2.1.2.1    | Devices for Membrane Plasmapheresis                                                                 | 40 |
| 2.1.2.2    | Devices for Centrifugal Apheresis Techniques                                                        | 41 |
| 2.1.3      | Recirculation Phenomena                                                                             | 43 |
| 2.1.3.1    | Recirculation in Single-Needle Technique                                                            | 43 |
| 2.1.3.2    | Investigations of Recirculation in Single-Needle Technique                                          | 46 |
| 2.1.4.     | Comparison of Single-Needle and Double-Needle Technique                                             | 48 |
| <b>2.2</b> | <b>Membrane Technology</b>                                                                          | 49 |
| 2.2.1      | Basic Principles of Filtration                                                                      | 49 |
| 2.2.2      | Physical Foundations and Membrane Separation Processes                                              | 50 |
| 2.2.3      | Membrane Structure                                                                                  | 54 |
| 2.2.4      | Sieving Behaviour for Macromolecular Substances Using Various Membranes                             | 59 |
| 2.2.5      | Application of Polypropylene and Cellulose Diacetate Membranes: Side Effects and Technical Problems | 62 |
| 2.2.6      | Clinical Tests of a Polycarbonate Membrane Separator                                                | 63 |
| 2.2.7      | Biocompatibility                                                                                    | 67 |
| 2.2.7.1    | Membranes                                                                                           | 68 |
| 2.2.7.2    | Adsorption Systems                                                                                  | 70 |
| 2.2.7.2.1  | Microparticle Release from Adsorber Used for LDL-Apheresis                                          | 71 |
| 2.2.7.3    | Interaction Between Extracorporeal Surfaces and Blood                                               | 75 |
| 2.2.7.4    | Methods of Manufacturing Compatible Membranes                                                       | 78 |
| <b>2.3</b> | <b>Material Kinetics</b>                                                                            | 78 |
| 2.3.1      | Flow Behaviour in Hollow Fibers                                                                     | 79 |
| 2.3.2      | The Kinetics of TPE                                                                                 | 82 |
| 2.3.2.1    | One Compartment Model                                                                               | 82 |
| 2.3.2.2    | Material Kinetics with the Single-Needle Method                                                     | 84 |
| 2.3.2.3    | Results with the One Compartment Model                                                              | 84 |

|            |                                                                            |            |
|------------|----------------------------------------------------------------------------|------------|
| 2.3.3      | Elimination of an Artificial Immune Complex by TPE .....                   | 89         |
| 2.3.4      | Elimination of Coagulation Factors by TPE .....                            | 93         |
| 2.3.5      | Elimination of various Hormones by TPE .....                               | 94         |
| 2.3.6      | Elimination of various Immunoglobulins by TPE .....                        | 97         |
| <b>2.4</b> | <b>Methods of TPE .....</b>                                                | <b>104</b> |
| 2.4.1      | Blood Access .....                                                         | 104        |
| 2.4.1.1    | Catheter and Material .....                                                | 104        |
| 2.4.1.2    | Surface-Treatment Technologies for Catheters .....                         | 107        |
| 2.4.2      | Exchange Volumes and Frequencies of TPE .....                              | 113        |
| 2.4.3      | Immunoadsorption, LDL-Apheresis .....                                      | 115        |
| 2.4.4      | Substitution Possibilities .....                                           | 115        |
| 2.4.5      | Anticoagulation in TPE .....                                               | 121        |
| 2.4.6      | Additional Medication Therapy in TPE .....                                 | 122        |
| <b>2.5</b> | <b>Selective Separation Methods .....</b>                                  | <b>124</b> |
| 2.5.1      | Historical Overview .....                                                  | 124        |
| 2.5.2      | Equipment for Selective Separation Techniques .....                        | 126        |
| 2.5.3      | Cascade Filtration .....                                                   | 127        |
| 2.5.3.1    | Technical Aspects of Cascade Filtration .....                              | 128        |
| 2.5.3.2    | Kinetics of Cascade Filtration .....                                       | 130        |
| 2.5.3.3    | Results of Cascade Filtration and Indications .....                        | 131        |
| 2.5.4      | Cryofiltration .....                                                       | 132        |
| 2.5.5      | Thermofiltration .....                                                     | 133        |
| 2.5.6      | Unselective Adsorption .....                                               | 133        |
| 2.5.6.1    | Active Charcoal .....                                                      | 133        |
| 2.5.6.2    | Ion Exchange Resins and Polymeric Adsorbents .....                         | 134        |
| 2.5.6.3    | Plasmaperfusion .....                                                      | 135        |
| 2.5.7      | Selective Adsorption .....                                                 | 136        |
| 2.5.7.1    | Specific Adsorption .....                                                  | 136        |
| 2.5.7.2    | Protein A Immunoadsorption .....                                           | 136        |
| 2.5.7.2.1  | Immunosorba® System .....                                                  | 138        |
| 2.5.7.2.2  | Prosorba® System .....                                                     | 141        |
| 2.5.7.2.3  | Anti-IgG Immunoadsorption .....                                            | 141        |
| 2.5.7.3    | Fibrinogen Adsorption .....                                                | 142        |
| 2.5.7.4    | LDL-Apherese .....                                                         | 142        |
| 2.5.7.4.1  | Imunoadsorption .....                                                      | 144        |
| 2.5.7.4.2  | Heparin-induced LDL-precipitation (HELP system) .....                      | 145        |
| 2.5.7.4.3  | LDL-Adsorption with Dextran sulfate .....                                  | 146        |
| 2.5.7.4.4  | LDL Hemoperfusion System .....                                             | 147        |
| 2.5.7.4.5  | Lipoprotein (a)- Apheresis .....                                           | 148        |
| 2.5.7.5    | Different Adsorbents .....                                                 | 149        |
| 2.5.7.6    | Electrophoretic Separation Processes .....                                 | 150        |
| 2.5.7.7    | Selective Plasma Separation Combined Techniques .....                      | 150        |
| 2.5.7.8    | BioLogic-DTPP System .....                                                 | 150        |
| 2.5.7.9    | Molecular Adsorbent Recycling System (MARS) .....                          | 151        |
| 2.5.7.10   | Enzyme Adsorbents (Bioreactor) .....                                       | 151        |
| 2.5.7.10.1 | Tryptophan Side Chain Oxidase (TSO) .....                                  | 151        |
| 2.5.7.11   | Immunopheresis of Soluble Tumor Necrosis Faktor Inhibitors in Cancer ..... | 152        |

### 3. Efficacy and Indications of Therapeutic Apheresis (TA)

|            |                                                                                             |     |
|------------|---------------------------------------------------------------------------------------------|-----|
| <b>3.1</b> | <b>Pathophysiology and Clinical Aspects of Immunological and Non-Immunological Diseases</b> | 159 |
| 3.1.1      | Autoimmune Diseases                                                                         | 159 |
| 3.1.1.1    | Lysis                                                                                       | 159 |
| 3.1.1.2    | Inflammatory Tissue Reaction                                                                | 160 |
| 3.1.1.3    | Receptor Enzyme Blocade                                                                     | 160 |
| 3.1.2      | Immunocomplex Diseases                                                                      | 161 |
| 3.1.3      | Non-Immunological Diseases                                                                  | 164 |
| <b>3.2</b> | <b>Functioning Mechanism in Therapeutic Apheresis</b>                                       | 164 |
| 3.2.1      | Functioning Mechanism in Selective Separation Methods                                       | 167 |
| <b>3.3</b> | <b>Complications and Side Effects</b>                                                       | 168 |
| <b>3.4</b> | <b>Indications for TA</b>                                                                   | 173 |

### 4. Clinical Results

|            |                                                                                     |     |
|------------|-------------------------------------------------------------------------------------|-----|
| <b>4.1</b> | <b>Renal Diseases</b>                                                               | 181 |
| 4.1.1      | Rapidly Progressive Glomerulonephritis (RPGN)                                       | 182 |
| 4.1.1.1    | Basic Pathophysiological Aspects                                                    | 182 |
| 4.1.1.2    | Antibasement Membrane Antibody Glomerulonephritis (Goodpasture Syndrome, ABM-Ab-GN) | 184 |
| 4.1.1.3    | Immune Complex Nephritis (ICN)                                                      | 187 |
| 4.1.1.4    | RPGN with or without Glomerular Deposition (ANCA ab)                                |     |
|            | Pauci – Immune RPGN                                                                 | 188 |
| 4.1.1.5    | Therapy Recommendations for RPGN                                                    | 188 |
| 4.1.2      | Glomerulonephritis with Nephrotic Syndrome                                          | 189 |
| 4.1.3      | Hemolytic-Uremic Syndrome (HUS)                                                     | 192 |
| 4.1.3.1    | Basic Pathophysiologic Aspects                                                      | 192 |
| 4.1.3.2    | Therapeutic Interventions in HUS                                                    | 195 |
| 4.1.4      | Myoglobulinemic Renal Failure                                                       | 197 |
| 4.1.5      | Dialysis Encephalopathy                                                             | 200 |
| 4.1.6      | Kidney Transplant Rejection                                                         | 200 |
| 4.1.7      | Acute Renal Failure                                                                 | 200 |
| 4.1.7.1    | Causes of Acute Renal Failure                                                       | 201 |
| 4.1.7.2    | Basic Pathophysiologic Aspects of ARF                                               | 202 |
| <b>4.2</b> | <b>Neurological Diseases</b>                                                        | 204 |
| 4.2.1      | Guillain-Barre'syndrome                                                             | 205 |
| 4.2.2      | Myasthenia gravis                                                                   | 208 |
| 4.2.3      | Multiple Sclerosis                                                                  | 210 |
| 4.2.4      | Other Neurological Diseases                                                         | 213 |
| <b>4.3</b> | <b>Hematological Diseases</b>                                                       | 215 |
| 4.3.1      | Rhesus Incompatibility                                                              | 216 |

|            |                                                            |     |
|------------|------------------------------------------------------------|-----|
| 4.3.2      | Anemia                                                     | 217 |
| 4.3.2.1    | Hemolytic Anemia                                           | 218 |
| 4.3.2.2    | Autoimmune Hemolytic Anemia                                | 218 |
| 4.3.2.3    | Aplastic Anemia                                            | 220 |
| 4.3.3      | Thrombocytopenia                                           | 221 |
| 4.3.3.1    | Idiopathic Thrombocytopenic Purpura (ITP)                  | 221 |
| 4.3.3.2    | Thrombotic Thrombocytopenic Purpura (TTP)                  | 223 |
| 4.3.4      | Disseminated Intravascular Coagulation (DIC)               | 224 |
| 4.3.5      | Coagulopathy                                               | 225 |
| 4.3.5.1    | Hemophilia A                                               | 225 |
| 4.3.5.2    | Acquired Factor VIII Antibodies in Non-Hemophilic Patients | 226 |
| 4.3.6      | Hyperviscosity Syndrome                                    | 226 |
| 4.3.6.1    | Multiple Myeloma and Plasmocytoma                          | 226 |
| 4.3.6.2    | Morbus Waldenström                                         | 226 |
| <b>4.4</b> | <b>Gastroenterologic Diseases</b>                          | 227 |
| 4.4.1      | Liver Failure, Akute Liver Failure (ALF)                   | 227 |
| 4.4.1.1    | Basic Pathophysiological Aspects                           | 227 |
| 4.4.1.2    | Possible Therapies in Acute Liver Failure                  | 230 |
| 4.4.1.3    | Therapeutic Apheresis in Chronic Liver Disease             | 233 |
| 4.4.1.4    | Other Temporary Liver Support Systems                      | 234 |
| 4.4.2      | Acute Pancreatitis                                         | 236 |
| 4.4.3      | Other Gastroenterological Diseases                         | 237 |
| <b>4.5</b> | <b>Endocrinological and Metabolic Diseases</b>             | 237 |
| 4.5.1      | Thyroid Storm                                              | 237 |
| 4.5.1.1    | Basic Pathophysiological Aspects                           | 237 |
| 4.5.1.2    | Possible Therapies                                         | 238 |
| 4.5.2      | Endocrine Ophthalmopathy                                   | 241 |
| 4.5.3      | Type-I-Diabetes mellitus                                   | 241 |
| 4.5.3.1    | Basic Pathological Aspects                                 | 242 |
| 4.5.3.2    | Possible Therapeutic Measures                              | 242 |
| 4.5.4      | Hyperlipoproteinemia                                       | 243 |
| 4.5.4.1    | Basic Pathophysiological Aspects                           | 243 |
| 4.5.4.2    | Possible Therapeutic Measurements                          | 247 |
| 4.5.4.2.1  | Cascade Filtration                                         | 250 |
| 4.5.4.2.2  | Immunoadsorption                                           | 251 |
| 4.5.4.2.3  | Heparin-induced Cholesterol Precipitation (HELP)           | 253 |
| 4.5.4.2.4  | Dextran Sulfate Low-Density Lipoprotein (Liposorber)       | 254 |
| 4.5.4.2.5  | Low-density Lipoprotein Hemoperfusion (DALI)               | 257 |
| 4.5.4.3    | Conclusion                                                 | 258 |
| <b>4.6</b> | <b>Respiratory Diseases</b>                                | 258 |
| 4.6.1      | Asthma Bronchiale                                          | 258 |
| 4.6.2      | Churg-Strauss-Syndrome                                     | 259 |
| 4.6.3      | Wegener's Granulomatosis (WG)                              | 260 |
| <b>4.7</b> | <b>Dermatological Diseases</b>                             | 261 |
| 4.7.1      | Pemphigus vulgaris                                         | 261 |

|             |                                                              |     |
|-------------|--------------------------------------------------------------|-----|
| 4.7.1.1     | Bullous Pemphigoid                                           | 262 |
| 4.7.1.2     | D-Penicillinamine-induced Pemphigus                          | 263 |
| 4.7.2       | Other Forms of Dermatoses                                    | 264 |
| <b>4.8</b>  | <b>Autoimmune Diseases</b>                                   | 266 |
| 4.8.1       | Basic Pathophysiological Aspects                             | 266 |
| 4.8.2       | Systemic Lupus erythematosus (SLE)                           | 269 |
| 4.8.2.1     | Basic Pathophysiological Aspects                             | 269 |
| 4.8.2.2     | Possible Therapeutic Measures                                | 271 |
| 4.8.3       | Rheumatoid Arthritis                                         | 277 |
| 4.8.4       | Inflammatory Eye Diseases                                    | 277 |
| <b>4.9</b>  | <b>Oncological Diseases</b>                                  | 279 |
| 4.9.1       | Basic Pathophysiological Aspects and Chemotherapy Resistance | 279 |
| 4.9.2       | Possible Therapies                                           | 282 |
| 4.9.3       | Conclusion                                                   | 284 |
| <b>4.10</b> | <b>Infections (Septicemia)</b>                               | 285 |
| 4.10.1      | Basic Pathophysiological Aspects                             | 285 |
| 4.10.2      | Various Infectious Diseases                                  | 286 |
| 4.10.3      | Malaria Tropica                                              | 286 |
| <b>4.11</b> | <b>Exogenous Intoxications</b>                               | 289 |
| 4.11.1      | Basic Pathophysiological Aspects                             | 289 |
| 4.11.2      | Possible Therapies                                           | 290 |
| 4.11.3      | Conclusion                                                   | 291 |
| <b>4.12</b> | <b>Miscellany</b>                                            | 292 |
| <b>4.13</b> | <b>TPE in Children</b>                                       | 294 |
| <b>5.</b>   | <b>Appraisalment and Perspectives</b>                        |     |
| <b>5.1</b>  | <b>Critical Evaluation of TPE</b>                            | 299 |
| <b>5.2</b>  | <b>Future Perspectives</b>                                   | 304 |
| <b>6.</b>   | <b>Appendix</b>                                              |     |
| <b>6.1</b>  | <b>References</b>                                            | 309 |
| <b>6.2</b>  | <b>Index</b>                                                 | 409 |